Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybutimibe vs ezetimibe added to moderate-intensity statins in very-high- and extremely-high-risk ASCVD
ChiCTR2600122266Phase 4Not yet recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hybutimibe and ezetimibe in atherosclerotic disease (2 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Rate of change in LDL-C from baseline at 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
hybutimibeezetimibe
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2600122266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122266.